Quintrio
Home

PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS

Solesence, Inc. Common Stock

SLSN

Solesence Inc is a health-oriented, science-driven company, focused on various skin health, beauty and wellness markets. Its primary skin health products are fully developed prestige skin care formulations with mineral-based UV protection enabled by proprietary Active Pharmaceutical Ingredients, which are also marketed as APIs for sale to manufacturers of other types of skin health products, including sunscreens and daily care products. Additionally, it continues to sell products in legacy markets, including medical diagnostics, architectural coatings, industrial coating applications, abrasion-resistant additives, and plastics additives applications. The company operates as a single business segment.

Last trade $1.68
Day change +$0.08 (+5.00%)
Day range $1.52 – $1.87
Volume 562,619
Market cap $113M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$113.04M
Price / earnings
41.09×
Price / book
6.75×
Price / sales
1.86×
EV / sales
1.95×
EV / EBITDA
24.54×

Profitability

Earnings per share
$0.04
Return on assets
6.19%
Return on equity
16.42%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.44×
Current ratio
1.73×
Quick ratio
0.87×
Cash ratio
0.09×

Cash flow

Price / cash flow
11.03×
Price / free cash flow
11.54×
Free cash flow
$9.8M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SLSN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025
Revenue$20.16M$15.33M$12.96M$12.48M$14.6M$20.36M
Cost of revenue$12.24M$10.68M$9.79M$8.94M$11.12M$13.83M
Gross profit$7.93M$4.65M$3.17M$3.54M$3.47M$6.53M
Selling, general and administrative$2.81M$3.68M$2.8M$2.21M$3.07M$3.01M
Research and development$1.08M$947K$1.04M$1.04M$1.08M$955K
Total operating expenses$3.89M$4.63M$3.84M$3.25M$4.15M$3.97M
Operating income$4.04M$23K-$674K$296K-$677K$2.56M
Interest expense-$258K-$279K-$263K-$328K-$339K-$87K
Income before taxes$3.89M-$256K-$936K-$44K-$1.02M$3.71M
Income taxes$219K$0$0-$317K$0$390K
Net income$3.67M-$256K-$936K$273K-$1.02M$3.32M
Net income attributable to common shareholders$3.67M-$256K-$936K$273K-$1.02M$3.32M
EBITDA$4.35M$346K-$361K$517K-$452K$2.79M
Basic earnings per share$0.05$0.00-$0.01$0.00-$0.01$0.05
Diluted earnings per share$0.05$0.00-$0.01$0.00-$0.01$0.05

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Solésence Named Contract Manufacturing Partner of the Year in the 2026 Cosmetics Business Innovation Awards

Solésence, Inc. (Nasdaq: SLSN) has been named Contract Manufacturing Partner of the Year at the 2026 Cosmetics Business Innovation Awards by HPCi Media. The award recognizes the company's excellence in client satisfaction, innovation, product development, reliability, and speed-to-market. This marks the company's 12th industry award since 2022, reflecting its leadership in scientifically-driven health care solutions across beauty and life science categories.

GlobeNewswire Inc.

Solésence Supports Landmark Report on UV Safety in the United Kingdom as Member of UV Safety Coalition

Solésence, Inc. announced its support for a landmark UK report calling for a national UV safety strategy to combat ultraviolet radiation exposure. The report, led by the UK's APPG for Beauty, Hair & Wellbeing, includes 29 recommendations to shift public perception of UV protection and increase access to protective products. With melanoma cases projected to rise 9% by 2038, the report advocates for sustained government-led campaigns similar to Australia's successful 'Slip, Slop, Slap!' initiative.

GlobeNewswire Inc.

Solésence Reports Third Quarter 2025 Financial Results

Solésence reported a challenging Q3 2025 with decreased revenue and net loss, implementing strategic leadership changes and operational restructuring to drive future growth and efficiency.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.